AICAR
Also known as Acadesine, AICA-Riboside, AICA Ribonucleotide, 5-Aminoimidazole-4-carboxamide riboside
AICAR is an exercise-mimicking peptide that tricks your body into workout mode without moving a muscle. It activates a pathway called AMPK, which ramps up fat burning, boosts endurance, and improves heart health—like a molecular personal trainer.
Route
Subcutaneous injection
Dose range
1 mg – 3 mg
Frequency
Once per day (subcutaneous); maintain consistent AMPK activation
Cycle length
8–12 weeks
Overview
AICAR is an exercise-mimicking peptide that tricks your body into workout mode without moving a muscle. It activates a pathway called AMPK, which ramps up fat burning, boosts endurance, and improves heart health—like a molecular personal trainer. Research in animals showed it enhances stamina, helping run farther, and aids diabetes control by better using sugar for energy.
Common benefits spotlight weight management, muscle preservation during cuts, and metabolic tune-ups for energy crashes. It’s studied for heart protection and longevity, potentially slowing age-related decline. Injected or oral forms are explored, with low toxicity in trials. Ideal for athletes or those with limited mobility wanting fitness gains, though human data is emerging—exciting frontier for health optimization.
Studied benefits
- Acts as an exercise-mimetic to enhance endurance
- improves insulin sensitivity and fat metabolism
- potential for diabetic neuropathy protection
Reported side effects
- Remains experimental with unknown long-term risks
- possible mild local irritation at the injection site
Protocol
Dosing Schedule (Subcutaneous)
Educational reference only. Not medical advice. Research compounds are not approved for human use. Full disclaimer.
AICAR (50 mg)
Reconstitute with 3.0 mL bacteriostatic water (Final concentration: ~16.7 mg/mL).
Activate AMPK pathways to mimic exercise-like metabolic effects.
| Week/Phase | Daily Dose | Draw at 16.67 mg/mL | Log |
|---|---|---|---|
| Weeks 1–2 | 1,000 mcg (1 mg) | 6 units (0.06 mL) | + Log |
| Weeks 3–4 | 2,000 mcg (2 mg) | 12 units (0.12 mL) | + Log |
| Weeks 5–8 | 3,000 mcg (3 mg) | 18 units (0.18 mL) | + Log |
Frequency
Once per day (subcutaneous); maintain consistent AMPK activation.
Timing
Any consistent time; rotate injection sites daily.
Cycle length
8–12 weeks.
Unit calculator
Set your vial and water; the table above updates.
16.67 mg/mL
50 doses of 1 mg per vial
At the starting dose (1 mg × 7/week for a 8-week cycle) you would use about 56 mg, i.e. 2 × 50 mg vials. Higher phases use proportionally more.
Assumes a U-100 insulin syringe (100 units = 1 mL). Educational math only; verify every calculation yourself.
Context
Lifestyle considerations
Maintain a high-protein, balanced diet to provide adequate fuel for the metabolic adaptations and increased glucose uptake triggered by AICAR. Stay physically active with regular cardiovascular or endurance training to potentially amplify the peptide's AMPK-mediated effects, which mimic the physiological benefits of aerobic exertion. Ensure 7–9 hours of quality sleep to facilitate cellular recovery and mitochondrial repair. Maintain optimal hydration, particularly during exercise-based research, as AICAR influences fat oxidation and glucose metabolism pathways that depend on a stable internal environment.
Evidence
Research summaries
AICAR Improves Outcomes of Metabolic Syndrome and Type 2 Diabetes Induced by High-Fat Diet in C57Bl/6 Male Mice
Findings: Cuts body weight and belly fat from junk diets, lowers high blood sugar and insulin resistance, protects organs like liver and kidneys from fat damage.
High-fat diets (like endless fries) pack on pounds, spike sugars, and wreck insides—metabolic syndrome alert! AICAR flips AMPK switch, mimicking exercise: burns fat, fixes sugar uptake. In mice on fatty chow for 13 weeks, untreated ballooned (33g vs 27g normal), fat pads quadrupled. AICAR from week 7 dropped weights 10-15%, shrank epididymal fat 25-40%, eased HOMA-IR (insulin trouble score) from 12 to 7. Less visceral blobs at necropsy, healthier hearts/livers on slides. Glucose tests improved tolerance; cholesterol halved in treated. But early use caused mild liver stress—timing matters. Food intake dipped then stabilized. For teens dodging family diabetes, it's a pill workout: no gym, just balance. Stats solid (ANOVA p<0.001), necropsy fewer issues (hydronephrosis down).
Read the study ↗AICAR Ameliorates High-Fat Diet-Associated Pathophysiology in Mouse and Ex Vivo Models, Independent of Adiponectin
Findings: Reduces obesity inflammation in fat tissues, boosts metabolic health without needing fat hormones, protects against diet-driven diseases like fatty liver.
Fat tissue turns toxic on junk food, swelling and signaling bad stuff body-wide. AICAR calmed human fat explants and mice: less cytokines, better insulin action. High-fat mice lost weight, inflammation plunged regardless of adiponectin (fat signal). Ex vivo proofs: AMPK on slashed macrophage chaos. Hearts safer from ischemia. No toxicity flags. Picture taming a burger rebellion—cells burn fuel right. Great for young athletes overeating.
Read the study ↗AICAR Activates AMPK to Improve Glucose and Lipid Metabolism in Obesity Models
Findings: Mimics exercise for fat burn and sugar control, lowers heart risks from bad diets, potential for type 2 diabetes prevention in heavy kids.
AMPK is energy boss; AICAR wakes it when diets overload. Mice gained 50% weight on fat—hyperglycemia, hyperinsulinemia hit. AICAR trimmed gains, normalized glucose/insulin tests, cut lipids (cholesterol down 20%). Organs less fatty, locomotor anxiety eased. MTX combo didn't boost much. Trials hint human perks: muscle glucose up, liver output down. For 9th graders, dodge prediabetes without salads—metabolic reset button.
Read the study ↗More references (6)
- AMPK agonist AICAR improves cognition in aged mice, 2015
- Metabolomics Analysis of AICAR and Metabolic Pathways, 2015
- AICAR: An activator of AMP-activated protein kinase, 2012
- AICAR inhibits inflammation via AMPK-dependent pathways, 2010
- Chronic AICAR treatment and insulin sensitivity, 2003
- AICAR administration reduces metabolic disturbances in rats, 2002
Identification
Chemistry
- common names
- AICAR, Acadesine, AICA-Riboside, AICA Ribonucleotide, 5-Aminoimidazole-4-carboxamide-1-β-D-ribofuranoside, 5-Aminoimidazole-4-carboxamide riboside, AICA-Ribonucleoside, NSC 105823, Z-nucleotide, ZMP (when phosphorylated)
- cas
- -
- formula
- -
- molecular weight
- -
- source
- Synthetic pharmaceutical compound; does not exist in nature in significant quantities
- biosynthesis
- Produced via organic chemical synthesis; represents a mimic/analog of naturally occurring metabolic intermediates in purine metabolism
Keep exploring
Related peptides
5-Amino-1MQ
5-amino-1-methylquinolinium · NNMTi
- Route
- Subcutaneous
- Dose
- 2.5 mg – 5 mg
- Cycle
- 10–20 days (based on a single 50 mg vial)
Adipotide (FTPP)
FTPP · Adipotide
- Route
- Subcutaneous
- Dose
- 5 mcg – 20 mcg
- Cycle
- 21–28 days; monitoring of renal markers is standard
AOD-9604
AOD 9604 · Tyr-hGH fragment 177-191
- Route
- Subcutaneous
- Dose
- 200 mcg – 500 mcg
- Cycle
- 8–12 weeks
BPC-157, TB-500
- Route
- Subcutaneous
- Dose
- 333 mcg – 667 mcg
- Cycle
- 8–12 weeks